Christensen et al FEBS Lett. vol. 335 p. 345, Dec. 1993.* |
Denmeade et al Adv. in Pharm. vol. 35 p. 281, 1996.* |
Treimen et al., “A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases”, TiPS, Apr. 1998, vol. 19, pp 131-135. |
Anderen et al., “Ca2+-ATPase Inhibitory Activity Of a Locked Analogue of Thapsigargin”, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 5, pp 657-660, 1994. |
Nielsen et al., “Structure-Activity Relationships of Analogues of Thapsigargin Modified at O-11 and O-12”, J. Med. Chem., 1995, vol. 38, pp 272-276. |
Bourgeois et al., “Serpin-derived Peptide Substrates . . . Kallikreins hK1 and hK2”, The Journal of Biological Chemistry, vol. 272, No. 47, Issue of Nov. 21, pp. 29590-29595, 1997. |
Denmeade et al., “Specific and Efficient Peptide . . . of Prostate-specific Antigen”, Cancer Research, vol. 57, pp. 4924-4930, Nov. 1, 1997. |
Coombs et al., Substrate specificity of prostate-specific antigen (PSA), Chemistry & Biology, vol. 5, No. 9, Sep. 1998, pp 475-488. |
Brillard-Bourdet et al., “Substrate specificity . . . extended interaction site”, BBA, vol. 1246, No. 1, Jan. 5, 1995, pp. 47-52. |
Devi, “Consensus sequence . . . peptide precursors . . . sites”, FEBS Letters, vol. 280, No. 2, Mar. 25, 1991, pp 189-194. |
Nakayama et al., “Consensus Sequence for Precursor Processing at Mono-arginyl Sites”, The Journal of Biological Chemistry, vol. 267, No. 23, Issue of Aug. 15, pp. 16335-16340, 1992. |